Spyre Therapeutics, Inc. (SYRE) Investor Relations Documents

Spyre Therapeutics, Inc. (SYRE) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

Corporate Presentation: Spyre Therapeutics' I&I portfolio targets $40B+ GI, $30B+ Rheum, $5B+ Derm markets by 2030, with $1.1B cash and runway into 2H 2029.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-09-04Press releasePDF Version
2026-09-04Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-08-25Press releaseSpyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY0
2026-08-10PresentationCorporate Presentation
2026-08-10Press releasePDF Version
2026-08-10Press releaseSpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurati
2026-08-07Press releasePDF Version
2026-08-07Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-08-04Press releasePDF Version
2026-08-04Press releaseSpyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-02Press releasePDF Version
2026-07-02Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-06-15Press releasePDF Version
2026-06-15Press releaseSpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Se
2026-06-05Press releasePDF Version
2026-06-05Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-06-03Press releasePDF Version
2026-06-03Press releaseSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, a
2026-05-26Press releasePDF Version
2026-05-26Press releaseSpyre Therapeutics to Participate in Upcoming June Investor Conferences
2026-05-05Press releasePDF Version
2026-05-05Press releaseSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-01Press releasePDF Version
2026-05-01Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-04-16Press releasePDF Version
2026-04-16Press releaseSpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase
2026-04-14Press releasePDF Version
2026-04-14Press releaseSpyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
2026-04-13PresentationDownload Presentation
2026-04-13Press releasePDF Version
2026-04-13Press releasePDF Version
2026-04-13Press releaseSpyre Therapeutics Announces Proposed Public Offering of its Common Stock
2026-04-13Press releaseSpyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerat
2026-04-10Press releasePDF Version
2026-04-10Press releaseSpyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moder
2026-04-03Press releasePDF Version
2026-04-03Press releaseSpyre Therapeutics Announces Grants of Inducement Awards
2026-03-16Press releasePDF Version
2026-03-16Press releaseSpyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
2026-03-06Press releasePDF Version

SYRE overview · SYRE earnings · SYRE financials · SYRE KPIs · SYRE documents · SYRE ownership · SYRE peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.